Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical Industries has announced an agreement to sell its Teva-Takeda business venture in Japan to JKI Co., , a company established by private equity firm J-Will Partners. The divestment aligns with Teva's Pivot to Growth strategy and will allow the company to focus on its innovative medicines business in the Japanese market.

The transaction involves the transfer of all shares of Teva Takeda Pharma and its subsidiary Teva Takeda Yakuhin The deal is expected to complete by April 1, 2025, subject to regulatory approvals. All employees of the business venture will retain their positions under the agreement terms.

Teva Pharmaceutical announced positive Phase 3 SPACE trial results for AJOVY® (fremanezumab) in preventing episodic migraine in children and adolescents aged 6-17 years. The study demonstrated significant reductions in monthly migraine days (-2.5 vs -1.4; p=0.0210) and monthly headache days (-2.6 vs -1.5; p=0.0172) compared to placebo over 12 weeks.

The trial involved 237 participants with episodic migraine, showing a higher response rate of 47.2% vs 27.0% for placebo (p=0.0016). The treatment demonstrated favorable safety, with similar adverse event rates between treatment (55%) and placebo (49%) groups. Benefits were consistent across age subgroups and genders, marking the first successful Phase 3 trial of a CGRP-pathway treatment for pediatric migraine prevention.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. Richard Francis, President and CEO, and Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, will deliver a presentation on Thursday, December 5, 2024, at 8:20 A.M. Eastern Time. The presentation will be accessible via live webcast on Teva's Investor Relations website, with an archived version available within 24 hours after the live session.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced that their President and CEO, Richard Francis, will deliver a presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 8:30 AM GMT (3:30 AM ET). The presentation will be accessible via live webcast on Teva's Investor Relations website, with an archived version available within 24 hours after the live session concludes.

Teva Pharmaceutical reported strong Q3 2024 results with revenues of $4.3 billion, up 13% year-over-year. Key highlights include AUSTEDO U.S. revenues reaching $435 million (+28%), AJOVY global revenues of $137 million (+21%), and UZEDY U.S. revenues of $35 million. The generics business showed significant growth across all regions. Based on strong performance, Teva raised its 2024 outlook, projecting revenues of $16.1-$16.5 billion, Adjusted EBITDA of $4.7-$5.0 billion, and Non-GAAP EPS of $2.40-$2.50.

Teva Pharmaceuticals announced new interim results from the Phase 4 IMPACT-TD Registry study, revealing key differences in tardive dyskinesia (TD) experiences between patients with psychotic and mood disorders. The study, the largest of its kind, showed that fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%), despite similar AIMS scores.

The study also presented real-world patient experience data with AUSTEDO XR, showing that 87% reported satisfaction with the medication, and 74% reported improvement in their extra movements. The registry highlighted that TD significantly impacts quality of life regardless of underlying mental health conditions.

Teva Pharmaceuticals announced positive data from the Phase 3 SOLARIS trial of TEV-'749, a subcutaneous long-acting injectable for schizophrenia treatment. The trial demonstrated significant improvements in social functioning and quality of life across multiple measures from baseline to week 8. Key findings showed no Post-Injection Delirium/Sedation Syndrome events and met primary endpoints across all dosing groups. The company also presented real-world analyses of UZEDY®, showing high adherence rates (69%) among patients with various social challenges, including those with housing instability and food insecurity. The systemic safety profile was consistent with other approved oral formulations, with no new safety signals identified.

Teva Pharmaceuticals has announced its intention to appeal a European Commission decision regarding its practices related to COPAXONE®, a multiple sclerosis treatment. The company strongly disagrees with the Commission's decision, which it describes as based on extreme and untested legal theories lacking factual support.

The company has been cooperating with the EC since 2019 and states it will vigorously defend its position. Teva emphasizes its commitment to ethical business practices and continued support for MS patients, while noting it is financially prepared to mount its defense.

Alvotech and Teva announced FDA approval of a new presentation of SELARSDI™ (ustekinumab-aekn), expanding its label to include treatment of adults with Crohn's disease and ulcerative colitis. The approval is for a 130 mg/26 mL single-dose vial for intravenous infusion, complementing the previously approved 45 mg/0.5 mL and 90 mg/mL prefilled syringes for subcutaneous injection.

SELARSDI's U.S. launch for all indications is expected in Q1 2025. This approval aligns SELARSDI's label with the reference product Stelara® (ustekinumab). The companies highlighted successful launches of the first biosimilar ustekinumab in Canada, Japan, and Europe. Alvotech developed SELARSDI using the same cell line and process as the reference product.

This approval is part of a broader strategic partnership between Alvotech and Teva, which now includes nine biosimilar products.